4.3 Article

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases

Related references

Note: Only part of the references are listed.
Review Ophthalmology

Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways

Nelson S. Winkler et al.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2014)

Review Pharmacology & Pharmacy

Recent Progress in Prostaglandin F2α Ethanolamide (Prostamide F2α) Research and Therapeutics

D. F. Woodward et al.

PHARMACOLOGICAL REVIEWS (2013)

Article Dermatology

Increase in Matrix Metalloproteinase-2 Level in the Chicken Retina after Laser Photocoagulation

Masayuki Takeyama et al.

LASERS IN SURGERY AND MEDICINE (2010)

Article Ophthalmology

Versican and fibrillin-1 form a major hyaluronan-binding complex in the ciliary body

Akiko Ohno-Jinno et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)

Review Cardiac & Cardiovascular Systems

Prostanoids in the therapy of glaucoma

Naruhiro Ishida et al.

CARDIOVASCULAR DRUG REVIEWS (2006)

Review Ophthalmology

Ocular and systemic pharmacokinetics of latanoprost in humans

B Sjöquist et al.

SURVEY OF OPHTHALMOLOGY (2002)

Article Biochemistry & Molecular Biology

Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-α convertase activity but does not activate pro-MMP2

WR English et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2000)